Education
About Us
Working with TipRanks
Follow Us
Jeffrey Albers Insider Profile
4 Followers
Jeffrey Albers, Director at Blueprint Medicines, holds 152.40K shares in Blueprint Medicines (Ticker: BPMC), holds 27.36K shares in Spyre Therapeutics (Ticker: SYRE), holds 0.00 shares in Kymera Therapeutics (Ticker: KYMR).
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
-69.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jeffrey Albers holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Mar 26, 2024 - Mar 26, 2025
Return:+2.80%
The most profitable trade made by Jeffrey Albers
Jeffrey Albers's Trading History
Blueprint Medicines
Jan 23, 2025
Director
Uninformative Buy
360.50K
$13.28M
Dianthus Therapeutics
Jun 27, 2018
Director
Uninformative Buy
―
$99.77K
Kymera Therapeutics
Aug 26, 2024
Director
Uninformative Buy
51.70K
$0.00
Spyre Therapeutics
Nov 08, 2024
Director
Uninformative Sell
246.29K
$533.25K
List of latest transactions for each holding click on a transaction to see Jeffrey Albers's performance on stock
You May Also Like
Jeffrey Albers insider profile FAQ
What is the percentage of profitable transactions made by Jeffrey Albers?
The percentage of profitable transactions made by Jeffrey Albers is 33%.
What is the average return per transaction made by Jeffrey Albers?
The average return per transaction made by Jeffrey Albers is -69.50%.
What stocks does Jeffrey Albers hold?
Jeffrey Albers holds: BPMC, DNTH, KYMR, SYRE stocks.
What was Jeffrey Albers’s latest transaction?
Jeffrey Albers latest transaction was an Uninformative Buy of $360.50K.
What was Jeffrey Albers's most profitable transaction?
Jeffrey Albers’s most profitable transaction was an Informative Sell of BPMC stock on March 26, 2024. The return on the trade was 2.80%.
What is Jeffrey Albers's role in Blueprint Medicines?
Jeffrey Albers's role in Blueprint Medicines is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.